Abbott sees ‘strong’ financial performance in Q1

Sees FY gross margin “somewhat above” 59.5% of net sales. Sees FY net interest expense around $600M, adjusted tax rate around 15%. Sees MSD sales growth for established pharmaceuticals in Q1, mid to high single digits for FY. Sees low to mid single digit growth for Nutrition for Q1, FY19. Sees HSD sales growth for Q1, FY19 in Medical Devices.
https://thefly.com/landingPageNews.php?id=2852409